Regeneron Pharmaceuticals, Inc. | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (83)

Latest Posts

About This Stock More About This Stock
3 Top Biotech Stocks Worth Adding To Your Portfolio In 2024
Article By: Zacks Investment Research
Sunday, January 7, 2024 9:00 AM EST
Given the continuous need for innovative medical treatments, the biotech industry may be a haven despite its inherent volatility and an uncertain macroeconomic environment. Here are three top biotech stocks that will likely perform well in 2024.
In this article: REGN, SRPT, BGNE
Thoughts For Thursday: With War Clouds As A Backdrop The Market Is Set To End The Year On A High
Article By: David Marshall
Thursday, December 28, 2023 7:09 AM EST
The market looks set to end 2023 on a high note, but 2024 is less certain, particularly because though, the US does not want further action in the Gulf, it seems, Iran via its proxies is gaming for just that.
In this article: REGN, KMX, MRNA Also: BNO, SPX
Biotech Sector: On The Verge Of Triumph Or Turmoil?
Article By: Tactical Investor
Friday, October 6, 2023 2:37 AM EST
In this article, we delve into the Biotech Sector, exploring its promises, potential pitfalls, and the questions that arise.
In this article: REGN, AMGN, BIIB, GILD, VRTX
Large Cap Biopharmaceuticals Q1 2023: In This Bullish Run Biotech Lags
Article By: Rod Raynovich
Monday, April 3, 2023 1:14 PM EST
It was very difficult to make money in Q1 trading healthcare or biotech ETFs because of the sharp rally in other sectors. Nonetheless, there were two big winners.
In this article: REGN, VRTX, IBB Also: BMY, LLY, MRK, PFE, GILD, ABBV, XBI, XLV
Tuesday Talk: Where Is Santa?
Article By: TalkMarkets DailyTalk
Tuesday, December 20, 2022 5:21 AM EST
Monday continued the downtrend for the major indices on Wall Street which concluded a second week of losses on Friday. As for an annual Santa rally, that seems nowhere to be found.
In this article: T, WBD, LLY, MRK, UNH, REGN, GILD, VRTX, IWM, XBI, ABBV

Latest Tweets for $REGN

No tweets yet!



Regeneron Pharmaceuticals’ Dupixent Has Multi-Billion-Dollar Potential: Polen Capital
David J. Tanner 1/31/2018 3:55:05 AM

Note it has only been approved in Japan. And only for those whom existing treatments are ineffective. So that's a MUCH smaller market. How small I don't know. But not enough to make me bite. $REGN

1 to 1 of 1 comments